Once manufacturers, regulators and clinicians agree on consistent representation and description of the various attributes of a drug – the promise of ISO IDMP (Identification of Medicinal Products) data standards – it will be possible to assign globally-acceptable identifiers to drugs. Lise Stevens at Iperion Life Sciences Consultancy looks into the heightened case for IDMP in light of COVID-19.